BR0312506A - Composições transdérmicas de toxina botulìnica - Google Patents
Composições transdérmicas de toxina botulìnicaInfo
- Publication number
- BR0312506A BR0312506A BR0312506-8A BR0312506A BR0312506A BR 0312506 A BR0312506 A BR 0312506A BR 0312506 A BR0312506 A BR 0312506A BR 0312506 A BR0312506 A BR 0312506A
- Authority
- BR
- Brazil
- Prior art keywords
- botulinum toxin
- transdermal compositions
- neurotoxin
- patient
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"COMPOSIçõES TRANSDéRMICAS DE TOXINA BOTULìNICA". A presente invenção refere-se a composições farmacêuticas para administração transdérmica de neurotoxinas a um paciente que incluem uma neurotoxina, tal como toxina botulínica, e um agente de realçamento que facilita a absorção da neurotoxina através da pele do paciente e não elimina a bioatividade associada com a neurotoxina. As composições farmacêuticas são aplicadas topicamente em um paciente, e podem ser providas em um emplastro transdérmico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/194,805 US20040009180A1 (en) | 2002-07-11 | 2002-07-11 | Transdermal botulinum toxin compositions |
PCT/US2003/021351 WO2004006954A2 (en) | 2002-07-11 | 2003-07-08 | Transdermal botulinum toxin compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312506A true BR0312506A (pt) | 2005-04-12 |
Family
ID=30114842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312506-8A BR0312506A (pt) | 2002-07-11 | 2003-07-08 | Composições transdérmicas de toxina botulìnica |
Country Status (15)
Country | Link |
---|---|
US (5) | US20040009180A1 (pt) |
EP (1) | EP1521593B1 (pt) |
JP (2) | JP2005538082A (pt) |
KR (1) | KR101041698B1 (pt) |
CN (1) | CN100546648C (pt) |
AT (1) | ATE430579T1 (pt) |
AU (1) | AU2003267987B2 (pt) |
BR (1) | BR0312506A (pt) |
CA (1) | CA2492029A1 (pt) |
DE (1) | DE60327528D1 (pt) |
DK (1) | DK1521593T3 (pt) |
ES (1) | ES2323497T3 (pt) |
MX (1) | MXPA05000134A (pt) |
NZ (1) | NZ537231A (pt) |
WO (1) | WO2004006954A2 (pt) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US9066943B2 (en) * | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
DK2364734T3 (en) * | 2000-07-21 | 2017-10-30 | Revance Therapeutics Inc | Biological multicomponent transport systems |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
EP1443932B1 (en) | 2001-11-15 | 2012-12-26 | Micro Algae Corporation | Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
US7666435B2 (en) * | 2002-08-19 | 2010-02-23 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
US20040115222A1 (en) * | 2002-09-06 | 2004-06-17 | Michael Kane | Method for reduction of wrinkles |
US20060153876A1 (en) * | 2003-02-24 | 2006-07-13 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease |
WO2004084839A2 (en) * | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US8974774B2 (en) * | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application of botulotoxins and transdermal delivery |
US20080031898A1 (en) * | 2004-03-26 | 2008-02-07 | David Nathaniel E | Compositions and methods to increase the effect of a neurotoxin treatment |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
JP5047782B2 (ja) * | 2004-05-07 | 2012-10-10 | ファイトトックス リミテッド | フィコトキシン及びその使用 |
MXPA06012960A (es) * | 2004-05-07 | 2007-06-12 | Phytotox Ltd | Administracion transdermal de ficotoxinas. |
US7922983B2 (en) * | 2005-07-28 | 2011-04-12 | Kimberly-Clark Worldwide, Inc. | Sterilization wrap with additional strength sheet |
GB2417419A (en) * | 2004-07-12 | 2006-03-01 | Ipsen Ltd | Therapeutic use of Botulinum toxin |
GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
CA2578250C (en) * | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US20060057165A1 (en) * | 2004-09-10 | 2006-03-16 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
US7906124B2 (en) * | 2004-09-18 | 2011-03-15 | Asthmatx, Inc. | Inactivation of smooth muscle tissue |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
US7897147B2 (en) | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
KR20070091630A (ko) * | 2004-12-29 | 2007-09-11 | 라보 코스프로파르 아게 | 표정 주름을 이완시키는데 적합한 피부 적용을 위한 미용조성물 |
US7749515B2 (en) * | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
NZ560799A (en) | 2005-03-03 | 2009-10-30 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
ZA200707352B (en) | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
KR101430767B1 (ko) | 2005-07-18 | 2014-08-19 | 유니버시티 오브 메사츄세츠 로웰 | 나노에멀젼 조성물 및 이의 제조 및 사용 방법 |
EP1747782A1 (en) | 2005-07-19 | 2007-01-31 | Cesare Montecucco | Products for topical application comprising lysophospholipids and fatty acids |
EP1906923B1 (en) | 2005-07-22 | 2018-01-24 | The Foundry, LLC | Systems and methods for delivery of a therapeutic agent |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US9511210B2 (en) | 2006-05-19 | 2016-12-06 | The Foundry, Llc | Apparatus for toxin delivery to the nasal cavity |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US8518414B2 (en) * | 2005-11-17 | 2013-08-27 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
KR102110379B1 (ko) * | 2005-12-01 | 2020-05-14 | 유니버시티 오브 메사츄세츠 로웰 | 보툴리눔 나노에멀젼 |
AU2013234398B2 (en) * | 2005-12-01 | 2016-05-19 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
EP2172210A1 (en) | 2005-12-23 | 2010-04-07 | Partnership&Corp. Technology Transfer | Synthetic peptides for use as inhibitors of neurotransmitter secretion |
US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
US8658391B2 (en) * | 2006-04-27 | 2014-02-25 | Anterios, Inc. | Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
US20090304747A1 (en) * | 2006-05-16 | 2009-12-10 | Mayo Foundation For Medical Education And Research | Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
US7445783B2 (en) * | 2006-10-30 | 2008-11-04 | Cappellos, Inc. | Topical and transdermal treatments using urea formulations |
WO2008070538A2 (en) * | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
JP5292304B2 (ja) | 2006-12-01 | 2013-09-18 | アンテリオス, インコーポレイテッド | ペプチドナノ粒子およびその使用 |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
BRPI0720729A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa. |
AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
KR20150028856A (ko) | 2007-05-31 | 2015-03-16 | 안테리오스, 인코퍼레이티드 | 핵산 나노입자 및 이의 용도 |
KR101722038B1 (ko) | 2007-07-26 | 2017-04-03 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
WO2009021232A2 (en) * | 2007-08-09 | 2009-02-12 | Massachusetts Institute Of Technology | High-throughput, whole-animal screening system |
CN101918021A (zh) * | 2007-10-23 | 2010-12-15 | 阿勒根公司 | 使用经修饰的梭菌毒素治疗泌尿生殖系统神经疾病的方法 |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
KR101719824B1 (ko) | 2008-05-09 | 2017-04-04 | 호라이라 인코포레이티드 | 기관지나무 치료용 시스템, 어셈블리 및 방법 |
CN102076333A (zh) | 2008-06-26 | 2011-05-25 | 安特里奥公司 | 真皮递送 |
US8697155B2 (en) * | 2008-07-22 | 2014-04-15 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
DE102008034453A1 (de) * | 2008-07-24 | 2010-02-11 | Lts Lohmann Therapie-Systeme Ag | Verfahren zum Herstellen eines Mehrschichtenverbundes auf einer CIP-fähigen Beschichtungsanlage und Verwendung des damit hergestellten Mehrschichtenverbundes für die transdermale Applikation oder die Applikation in Körperhöhlen |
US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
KR102005930B1 (ko) | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
DK2413947T3 (da) * | 2009-04-01 | 2020-06-02 | Revance Therapeutics Inc | Fremgangsmåder og sammensætninger til behandling af hudtilstande forbundet med vaskulær hyperreaktivitet |
EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
BRPI1015938A2 (pt) | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
WO2011022707A1 (en) | 2009-08-21 | 2011-02-24 | Henk-Andre Kroon | Vesicular formulations |
US8147848B2 (en) | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
CA2774951C (en) | 2009-09-24 | 2014-12-16 | Allergan, Inc. | Method of treating osteoporosis with a neurotoxin |
EP2926757B1 (en) | 2009-10-27 | 2023-01-25 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
AU2010319477A1 (en) | 2009-11-11 | 2012-05-24 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
CA2814054A1 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
US20120189677A1 (en) * | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
DK2667854T3 (en) | 2011-01-24 | 2019-04-23 | Anterios Inc | NANO PARTICLE FORMATIONS |
US20120328701A1 (en) | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
CN103501802B (zh) * | 2011-06-27 | 2016-03-16 | 金相德 | 皮肤疤痕治疗用药物组合物及利用其的皮肤疤痕治疗方法 |
US20170360867A1 (en) * | 2011-11-11 | 2017-12-21 | Nova Neura, Llc | Pain Relieving System |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
ES2424294B1 (es) | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
BR112014025396B1 (pt) | 2012-04-13 | 2020-03-17 | Lubrizol Advanced Materials, Inc. | Composto, composição cosmética ou farmacêutica, e, uso de um composto |
EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
GB201208384D0 (en) * | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
US9199044B2 (en) | 2012-08-06 | 2015-12-01 | Elwha Llc | Devices and methods for wearable injection guides |
RU2506054C1 (ru) * | 2012-10-22 | 2014-02-10 | Елена Александровна Рогожкина | Способ лечения хронической анальной трещины |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014147255A1 (en) | 2013-03-22 | 2014-09-25 | Lipotec S.A. | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US20160279401A1 (en) | 2015-03-27 | 2016-09-29 | Allergan, Inc. | Dissolvable microneedles for skin treatment |
RU2670135C2 (ru) * | 2014-05-29 | 2018-10-18 | Проуселл Терапьютикс Инк. | Новый проникающий в клетки пептид, его конъюгат с ботулотоксином и их применение |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
KR102203633B1 (ko) * | 2015-04-14 | 2021-01-15 | 주식회사 엘지생활건강 | 칼슘채널 차단제 전달용 용해성 미세바늘 |
US10391289B2 (en) | 2015-04-13 | 2019-08-27 | Lg Household & Health Care Ltd. | Soluble microneedle containing ingredient for controlling release of neurotransmitters |
WO2016167545A1 (ko) * | 2015-04-13 | 2016-10-20 | 주식회사 엘지생활건강 | 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들 |
HRP20211669T1 (hr) | 2015-06-30 | 2022-02-18 | Sequessome Technology Holdings Limited | Multifazni pripravci |
WO2017063743A1 (en) * | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
US20170209553A1 (en) * | 2016-01-22 | 2017-07-27 | Transderm, Inc. | Delivery of botulinum with microneedle arrays |
KR101876177B1 (ko) * | 2016-02-17 | 2018-07-09 | 가톨릭관동대학교산학협력단 | 경피투과 보툴리눔 독소 패치 |
CN109803672A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 稳定的非蛋白质梭菌毒素组合物 |
EP3541358A1 (en) | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
US11065428B2 (en) | 2017-02-17 | 2021-07-20 | Allergan, Inc. | Microneedle array with active ingredient |
CN110691579A (zh) * | 2017-03-22 | 2020-01-14 | 邦蒂公司 | 用于治疗的肉毒杆菌神经毒素 |
CN106890196A (zh) * | 2017-04-07 | 2017-06-27 | 青岛东海药业有限公司 | 酪酸梭菌在制备预防或治疗帕金森病制剂中的应用 |
US11400136B2 (en) | 2017-06-19 | 2022-08-02 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
WO2019126502A1 (en) | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation |
US11191819B2 (en) | 2018-08-28 | 2021-12-07 | Ira Sanders | Skin therapeutics |
CN118121545A (zh) * | 2018-11-19 | 2024-06-04 | 奥维嘉生物科技(北京)有限公司 | 一种制备柔性脂质体的方法 |
SG11202104838SA (en) | 2018-12-03 | 2021-06-29 | Eirion Therapeutics Inc | Improved delivery of large agents |
EP3927327A4 (en) * | 2019-02-20 | 2022-11-02 | Regresar Medical, Inc. | METHODS AND DEVICES FOR LOCATING COMPOSITIONS |
US20240024220A1 (en) * | 2019-05-11 | 2024-01-25 | Youngsuk Yi | Neurotoxin compositions and methods |
SG11202110518XA (en) | 2019-05-14 | 2021-10-28 | Eirion Therapeutics Inc | Delaying peak effect and/or extending duration of response |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675009A (en) * | 1977-11-07 | 1987-06-23 | Lec Tec Corporation | Drug dispensing device for transdermal delivery of medicaments |
AU98530S (en) * | 1985-06-20 | 1987-11-05 | Novartis Ag | Subdivided membrane controlled transdermal device |
US5008110A (en) * | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
CA2067754C (en) * | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
US6939852B2 (en) * | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1261849B (it) * | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
US5814599A (en) * | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
AU688452B2 (en) * | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US5587396A (en) * | 1994-08-26 | 1996-12-24 | Mary Kay Inc. | Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
DE69627963T2 (de) * | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
DE69624668T2 (de) * | 1995-07-25 | 2003-08-28 | Massachusetts Institute Of Technology, Cambridge | Verbesserter transdermaler transport unter verwendung von ultraschall |
US6002961A (en) * | 1995-07-25 | 1999-12-14 | Massachusetts Institute Of Technology | Transdermal protein delivery using low-frequency sonophoresis |
US6234990B1 (en) * | 1996-06-28 | 2001-05-22 | Sontra Medical, Inc. | Ultrasound enhancement of transdermal transport |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US5948433A (en) * | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US6063768A (en) * | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
JP2002500075A (ja) * | 1998-01-08 | 2002-01-08 | ソントラ メディカル, インコーポレイテッド | 超音波伝達で増強される経皮輸送 |
ATE247979T1 (de) * | 1998-02-25 | 2003-09-15 | Us Gov Sec Army | Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort |
US5965154A (en) * | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19852981A1 (de) * | 1998-11-17 | 2000-05-18 | Martin Schmidt | Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen |
DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
US6565832B1 (en) * | 2000-01-31 | 2003-05-20 | Schering-Plough Healthcare Products, Inc. | Spray composition with reduced dripping |
EP1284137B1 (en) | 2000-05-26 | 2010-12-01 | TAKADA, Kanji | Nonoral preparation having three-layer structure |
US6565532B1 (en) * | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
DK2364734T3 (en) | 2000-07-21 | 2017-10-30 | Revance Therapeutics Inc | Biological multicomponent transport systems |
US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US9308181B2 (en) * | 2006-03-06 | 2016-04-12 | Nuvo Research Inc. | Topical formulations, systems and methods |
WO2012103040A1 (en) * | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Paraben compositions |
-
2002
- 2002-07-11 US US10/194,805 patent/US20040009180A1/en not_active Abandoned
-
2003
- 2003-07-08 AT AT03748935T patent/ATE430579T1/de active
- 2003-07-08 NZ NZ537231A patent/NZ537231A/en not_active IP Right Cessation
- 2003-07-08 ES ES03748935T patent/ES2323497T3/es not_active Expired - Lifetime
- 2003-07-08 DE DE60327528T patent/DE60327528D1/de not_active Expired - Lifetime
- 2003-07-08 BR BR0312506-8A patent/BR0312506A/pt not_active IP Right Cessation
- 2003-07-08 AU AU2003267987A patent/AU2003267987B2/en not_active Ceased
- 2003-07-08 MX MXPA05000134A patent/MXPA05000134A/es active IP Right Grant
- 2003-07-08 JP JP2004521565A patent/JP2005538082A/ja active Pending
- 2003-07-08 CN CNB038163985A patent/CN100546648C/zh not_active Expired - Fee Related
- 2003-07-08 DK DK03748935T patent/DK1521593T3/da active
- 2003-07-08 EP EP03748935A patent/EP1521593B1/en not_active Expired - Lifetime
- 2003-07-08 CA CA002492029A patent/CA2492029A1/en not_active Abandoned
- 2003-07-08 WO PCT/US2003/021351 patent/WO2004006954A2/en active IP Right Grant
- 2003-07-08 KR KR1020057000293A patent/KR101041698B1/ko active IP Right Grant
- 2003-09-29 US US10/675,172 patent/US7758871B2/en not_active Expired - Fee Related
- 2003-09-29 US US10/675,020 patent/US20050175636A1/en not_active Abandoned
-
2005
- 2005-06-22 US US11/159,511 patent/US7704524B2/en not_active Expired - Fee Related
-
2007
- 2007-10-30 US US11/929,871 patent/US9144692B2/en not_active Expired - Fee Related
-
2010
- 2010-09-27 JP JP2010214831A patent/JP2011037866A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DK1521593T3 (da) | 2009-08-03 |
US7704524B2 (en) | 2010-04-27 |
KR101041698B1 (ko) | 2011-06-14 |
JP2011037866A (ja) | 2011-02-24 |
US7758871B2 (en) | 2010-07-20 |
ATE430579T1 (de) | 2009-05-15 |
US20050074461A1 (en) | 2005-04-07 |
CN1668327A (zh) | 2005-09-14 |
WO2004006954A3 (en) | 2004-03-25 |
AU2003267987B2 (en) | 2006-08-17 |
ES2323497T3 (es) | 2009-07-17 |
MXPA05000134A (es) | 2005-04-11 |
WO2004006954A2 (en) | 2004-01-22 |
US9144692B2 (en) | 2015-09-29 |
EP1521593B1 (en) | 2009-05-06 |
KR20050025320A (ko) | 2005-03-14 |
US20080220020A1 (en) | 2008-09-11 |
AU2003267987A1 (en) | 2004-02-02 |
NZ537231A (en) | 2008-04-30 |
CN100546648C (zh) | 2009-10-07 |
US20060188525A1 (en) | 2006-08-24 |
US20050175636A1 (en) | 2005-08-11 |
JP2005538082A (ja) | 2005-12-15 |
EP1521593A2 (en) | 2005-04-13 |
US20040009180A1 (en) | 2004-01-15 |
DE60327528D1 (de) | 2009-06-18 |
CA2492029A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312506A (pt) | Composições transdérmicas de toxina botulìnica | |
BRPI0516836A (pt) | composições de neurotoxina cosméticas compreendendo um componente de toxina botulina e métodos | |
DK0759747T3 (da) | Transdermal indretning til administration gennem de-epitheliseret hud | |
WO2006089114A3 (en) | Methods and compositions for treating an anthrax toxin mediated condition | |
SG160357A1 (en) | Compositions and methods for topical application and transdermal delivery of botulinum toxins | |
BR0108173A (pt) | Composições farmacêuticas de toxina de botulina | |
MXPA03002576A (es) | Metodos para tratar lesiones musculares. | |
TW200616650A (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
AU9163701A (en) | Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid | |
DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
BRPI0518255A2 (pt) | mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica | |
AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
BR0307496A (pt) | Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária | |
ATE245452T1 (de) | Hyaluronatlyase als penetrationsförderer in topischen mitteln | |
DE502005009568D1 (de) | Pharmazeutische Zubereitungen als Hydrogel, die Diaminooxidase enthalten | |
BRPI0415755A (pt) | antagonistas do receptor b1 de bradiquinina | |
DE602006009259D1 (de) | Pharmazeutische zusammensetzung mit einem organopoirkstoff | |
EP1178796A4 (en) | AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE | |
WO2005117871A3 (en) | Pharmaceutical compositions for the treatment of pruritus | |
DK1280558T3 (da) | Halvfast indgivelsesvehikel og farmaceutiske sammensætninger | |
ATE256392T1 (de) | Verwendung von polyaminosäurederivate als konservierungsmittel | |
BRPI0611526A2 (pt) | composição tópica contendo gelatina | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
AR050673A1 (es) | Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |